Last reviewed · How we verify

Biogen Inc. — Portfolio Competitive Intelligence Brief

Biogen Inc. (BIIB) pipeline: 23 marketed, 0 filed, 13 Phase 3, 28 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BIIB (NASDAQ) 23 marketed 0 filed 13 Phase 3 28 Phase 2 54 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Zurzuvae ZURANOLONE marketed Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] GABA A receptor alpha-4/beta-3/delta Neuroscience 2023-01-01
Skyclarys OMAVELOXOLONE marketed Nuclear factor erythroid 2-related factor 2 Other 2023-01-01
Qalsody TOFERSEN marketed Antisense Oligonucleotide [EPC] Superoxide dismutase 1 (SOD1) mRNA Rare Disease 2023-01-01
Aduhelm ADUCANUMAB marketed Amyloid Beta-directed Antibody Amyloid beta A4 protein Immunology 2021-01-01
Vumerity DIROXIMEL FUMARATE marketed Hydroxycarboxylic acid receptor 2 Immunology 2019-01-01
Spinraza NUSINERSEN marketed Survival Motor Neuron-2-directed RNA Interaction [EPC] Other 2016-01-01
Plegridy PEGINTERFERON BETA-1A marketed Interferon beta [EPC] Interferon alpha/beta receptor Immunology 2014-01-01
Tecfidera DIMETHYL FUMARATE marketed dimethyl fumarate Hydroxycarboxylic acid receptor 2 Immunology 2013-01-01
Tysabri NATALIZUMAB marketed Integrin Receptor Antagonist [EPC] α4β1 and α4β7 integrins Immunology 2004-01-01
Avonex INTERFERON BETA-1A marketed Interferon beta [EPC] Interferon alpha/beta receptor Neuroscience 1996-01-01
TOFIDENCE TOCILIZUMAB-BAVI marketed Interleukin-6 Receptor Antagonist [EPC] Other
injectable MS DMT injectable MS DMT marketed Immunomodulator (disease-modifying therapy) Neurology / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 4 shared drug classes
  2. GlaxoSmithKline · 3 shared drug classes
  3. Takeda · 3 shared drug classes
  4. Bayer · 3 shared drug classes
  5. Pfizer · 3 shared drug classes
  6. Merck Sharp & Dohme LLC · 2 shared drug classes
  7. Amgen · 2 shared drug classes
  8. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Biogen Inc.:

Cite this brief

Drug Landscape (2026). Biogen Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biogen. Accessed 2026-05-13.

Related